Inhaled epinephrine developer De Motu Cordis (DMC) announced that its CEO Peter O’Neill has stepped down and that Chief Financial Officer John Corbett will serve as Interim CEO. The company says that it is preparing for a clinical trial of its DMC-IH1 inhaled dry powder epinephrine. DMC has contracted with Catalent for services related to the development of the DPI for the treatment of anaphylaxis.
DMC Founder and Chief Medical Officer John Fraser commented, “We thank Peter for his leadership and positive contributions to DMC’s evolution over the past five and a half years. With John Corbett stepping into the role, we are well positioned to maintain momentum and deliver on our clinical and strategic objectives.”
Read the De Motu Cordis announcement
